Navigation Links
Peregrine Reports Data Showing Bavituximab's Potential to Shrink Prostate Tumors
Date:9/7/2007

most commonly diagnosed cancer in men, accounting for 30 percent of all male cancers, and prostate cancer is second only to lung cancer as a leading cause of male cancer deaths. Currently, there is no cure for locally advanced or metastatic prostate cancer.

"We are delighted that bavituximab shrank resistant human prostate tumors in this study, an important new sign of its potential anti-cancer efficacy," said Steven W. King, president and CEO of Peregrine. "Preclinically, we have now shown that adding bavituximab equivalent antibodies to combination regimens significantly enhances the anti-tumor activity of cancer chemotherapy, of hormone deprivation therapy and of radiation therapy in prostate, breast, lung, brain and pancreatic cancers. The breadth of these potential applications supports many options for future clinical studies."

Bavituximab is a monoclonal antibody that binds to a phospholipid called phosphatidylserine that is normally located inside normal cells, but which becomes exposed on the outside of the cells that line the blood vessels of tumors, creating a specific target for anti-cancer treatments. Bavituximab is believed to help mobilize the body's immune system to destroy the blood vessels needed for tumor growth and spread. In a Phase Ib trial in advanced cancer patients to assess its safety in combination with common chemotherapy agents, bavituximab plus chemotherapy appeared to have a safety profile consistent with chemotherapy alone and showed positive signs of clinical activity, achieving objective response or disease stabilization in 50% of the evaluable patients. A protocol for a Phase II trial of bavituximab in combination with chemotherapy in patients with non-small cell lung cancer (NSCLC) is currently undergoing regulatory review in India. Bavituximab is also in clinical trials in the U.S. in patients with advanced solid tumors and in patients co-infected with HCV and HIV.

This study, entitled "Vascular Targeting Antib
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Peregrine Pharmaceuticals Reports Positive Top-Line Results in Bavituximab Combination Therapy Trial in Advanced Cancer Patients
2. Positive Results Using Affitech-Identified Human Antibody That Blocks VEGF Binding to VEGF Receptor 2 in Preclinical Cancer Model Reported by Peregrine
3. Peregrine Pharmaceuticals Highlights Significant Advances in the Companys Clinical and Preclinical Cancer Programs Presented This Week at the AACR Annual Meeting
4. Data Presented at AACR Meeting Shows Peregrines Immunocytokine Fusion Proteins Reduce Growth of B-Cell Lymphoma Tumors by 85% in Preclinical Studies
5. Data Presented at AACR Meeting Show Peregrines Bavituximab Equivalent Can Generate Curative Immune Responses as Part of a Vaccine-Like Regimen in Preclinical Models of Aggressive Brain Cancer
6. Data Presented at AACR Meeting Shows Peregrines Selective Anti-VEGF Antibodies are as Effective as Avastin(R) in Preclinical Cancer Models
7. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
8. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
9. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
10. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
11. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... January 15, 2014 Shire plc (LSE: SHP, NASDAQ: ... of Fair Trading (OFT) approval condition to the announced tender offer ...   As a result of the waiver, the transaction ... complete the tender offer on January 24, 2014 following the currently ...
(Date:1/15/2014)... 2014 Tegra Medical is very pleased to announce the ... new Chief Executive Officer.  Mark was promoted from his current ... the company,s four facilities in Massachusetts , ... joined Tegra Medical in 2012 with 20+ years of broad-based ...
(Date:1/15/2014)... 2014 Reportlinker.com announces that a new ... catalogue: Insulin Pump ... http://www.reportlinker.com/p01957812/Insulin-Pump-Market--Forecast-–-Worldwide-Analysis.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Medical_Equipment_and_Supply ... Insulin Pumps are gaining strong acceptance ...
Breaking Medicine Technology:Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 3Tegra Medical Appoints New Chief Executive Officer 2Tegra Medical Appoints New Chief Executive Officer 3Insulin Pump Market & Forecast - Worldwide Analysis 2Insulin Pump Market & Forecast - Worldwide Analysis 3Insulin Pump Market & Forecast - Worldwide Analysis 4Insulin Pump Market & Forecast - Worldwide Analysis 5Insulin Pump Market & Forecast - Worldwide Analysis 6Insulin Pump Market & Forecast - Worldwide Analysis 7Insulin Pump Market & Forecast - Worldwide Analysis 8Insulin Pump Market & Forecast - Worldwide Analysis 9Insulin Pump Market & Forecast - Worldwide Analysis 10Insulin Pump Market & Forecast - Worldwide Analysis 11Insulin Pump Market & Forecast - Worldwide Analysis 12Insulin Pump Market & Forecast - Worldwide Analysis 13Insulin Pump Market & Forecast - Worldwide Analysis 14Insulin Pump Market & Forecast - Worldwide Analysis 15Insulin Pump Market & Forecast - Worldwide Analysis 16Insulin Pump Market & Forecast - Worldwide Analysis 17
... Calif., April 24, 2012  A dose of 10 milligrams (mg) ... fermented soy germ-based nutritional supplement is as effective as a ... significantly and is even more effective for relieving muscle and ... women published in the June Journal of Women,s Health ...
... April 24, 2012  The Intellectual Property & Science ... to support R&D pharmaceutical leaders with a new ... use by AstraZeneca executives. The rich visualization dashboard ... , the company,s flagship life sciences platform, ...
Cached Medicine Technology:Soy-Based S-equol Supplement Reduces Hot Flash Frequency, Muscle And Joint Pain In U.S. Postmenopausal Women 2Soy-Based S-equol Supplement Reduces Hot Flash Frequency, Muscle And Joint Pain In U.S. Postmenopausal Women 3Soy-Based S-equol Supplement Reduces Hot Flash Frequency, Muscle And Joint Pain In U.S. Postmenopausal Women 4Soy-Based S-equol Supplement Reduces Hot Flash Frequency, Muscle And Joint Pain In U.S. Postmenopausal Women 5Soy-Based S-equol Supplement Reduces Hot Flash Frequency, Muscle And Joint Pain In U.S. Postmenopausal Women 6Soy-Based S-equol Supplement Reduces Hot Flash Frequency, Muscle And Joint Pain In U.S. Postmenopausal Women 7Soy-Based S-equol Supplement Reduces Hot Flash Frequency, Muscle And Joint Pain In U.S. Postmenopausal Women 8Thomson Reuters Launches New Mobile Oncology Decision Support Solution for R&D Pharmaceutical Leaders 2
(Date:4/16/2014)... 16, 2014): Celldex Therapeutics, Inc. (NASDAQ: CLDX) announced ... of CDX-1401 in solid tumors, including long-term patient follow-up, ... (Vol 6 Issue 232). The data demonstrate robust antibody ... in patients with very advanced cancers and suggest that ...
(Date:4/16/2014)... , DOWNERS GROVE, Ill. April 16, 2014 ... of surveillance colonoscopy in average-risk patients with one to ... about 90 percent of cases. This may be an ... multicenter endoscopic database study to quantify adherence to guidelines ...
(Date:4/15/2014)... in the United States have nearly doubled since 1988, suggests ... Health, with obesity apparently to blame for the surge. The ... not hit all groups equally, with alarming increases in diabetes ... research reported in the April 15, 2014 issue of the ...
(Date:4/15/2014)... a decades-old medical mystery and in the process have found ... kill about 1.5 million people a year. The researchers say they ... that has been in use for more than 50 years ... it is to the microbes it attacks. , A report ...
(Date:4/15/2014)... California, San Diego School of Medicine have identified a mechanism ... liver disease and why the virus is able to persist ... pathogen, which infects an estimated 200 million people worldwide, attacks ... the cell,s innate ability to fight infection. It does this ...
Breaking Medicine News(10 mins):Health News:Celldex's Phase 1 study of CDX-1401 published in Science Translational Medicine 2Health News:Celldex's Phase 1 study of CDX-1401 published in Science Translational Medicine 3Health News:Celldex's Phase 1 study of CDX-1401 published in Science Translational Medicine 4Health News:Surveillance colonoscopy recommendations for average-risk patients with 1 to 2 small polyps consistent with guidelines 2Health News:Surveillance colonoscopy recommendations for average-risk patients with 1 to 2 small polyps consistent with guidelines 3Health News:Pre-diabetes and diabetes nearly double over the past 2 decades 2Health News:Potent, puzzling and (now less) toxic: Team discovers how antifungal drug works 2Health News:Potent, puzzling and (now less) toxic: Team discovers how antifungal drug works 3Health News:Breaking bad mitochondria 2
... China Healthcare Acquisition Corp. (the "Company") (NYSE Alternext ... meeting held today, March 5, 2009, its stockholders voted ... early distribution of the Company,s trust fund for the ... March 5, 2009. Today,s vote had the automatic effect ...
... FRANKLIN, Tenn., March 5 /PRNewswire/ -- ... services, today announced details for the release of its financial ... plans to issue its earnings release for the fourth quarter ... March 25, 2009, and will host a conference call on ...
... not getting services they need to prevent another attack, ... After suffering a stroke, the chances of having another ... aren,t getting the interventions they need to reduce that ... smoking cessation and exercise, and medical treatments, such as ...
... the Aspen Health Stewardship Project will unveil a new ... support of a roadmap for making smart, sustainable improvements ... which includes patient groups, and health employer and provider ... America by adopting a set of core principles to ...
... Re-enrollment OpportunitiesHARRISBURG, Pa., March 5 Insurance ... laid off from a job that offered health insurance ... provide them with relief on premiums and that now ... information."I want to let Pennsylvanians know that additional help ...
... it has received a $76 million grant from the Bill ... and young child nutrition in developing countries in Africa and ... to increase rates of exclusive breastfeeding and improve complementary feeding ... children die and millions more are permanently disabled as a ...
Cached Medicine News:Health News:China Healthcare Acquisition Corp. Announces Stockholder Approval of Charter Amendment to Permit Early Distribution of Its Trust Fund and to Permit Its Continued Existence Without Blank Check Company Provisions and Sets Payment Date 2Health News:Second Stroke Prevention Efforts Found Wanting 2Health News:Second Stroke Prevention Efforts Found Wanting 3Health News:Aspen Institute to Introduce Roadmap for Responsible Health Care Reform, New Coalition To Call For Sustainable Improvements 2Health News:Pennsylvanians Encouraged to Take Another Look at COBRA Options 2Health News:AED Receives Gates Foundation Grant to Improve Nutrition and Reduce Deaths Among Young Children in Developing Countries 2
...
...
... biomechanical properties influence the results and ... and may hold clues to diagnosing ... assessing the biomechanical properties of corneal ... practitioners and researchers to measuring purely ...
The Surgiflex WAVE is a comfortable, easy to use, versatile, and interchangeable suction-irrigation device....
Medicine Products: